
1. antimicrob agents chemother. 2011 mar;55(3):961-6. doi: 10.1128/aac.01220-10.
epub 2010 dec 6.

ex vivo activity histone deacetylase inhibitors multidrug-resistant
clinical isolates plasmodium falciparum p. vivax.

marfurt j(1), chalfein f, prayoga p, wabiser f, kenangalem e, piera ka, fairlie
dp, tjitra e, anstey nm, andrews kt, price rn.

author information: 
(1)menzies school health research, p.o. box 41096, casuarina, darwin, nt 0811,
australia.

histone acetylation plays important role regulating gene transcription 
silencing plasmodium falciparum. histone deacetylase (hdac) inhibitors,
particularly hydroxamate class, shown potent in
vitro activity drug-resistant -sensitive laboratory strains p.
falciparum, raising potential new class antimalarial compounds. 
the current study, stage-specific ex vivo susceptibility profiles of
representative hydroxamate-based hdac inhibitors suberoylanilide hydroxamic acid 
(saha), 2-asa-9, 2-asa-14 (2-asa-9 2-asa-14 2-aminosuberic acid-based
hdac inhibitors) assessed multidrug-resistant clinical isolates p.
falciparum (n = 24) p. vivax (n = 25) papua, indonesia, using modified
schizont maturation assay. submicromolar concentrations saha, 2-asa-9, and
2-asa-14 inhibited growth p. falciparum (median 50% inhibitory
concentrations [ic₅₀s] 310, 533, 266 nm) p. vivax (median ic₅₀s of
170, 503, 278 nm). inverse correlation patterns hdac inhibitors and
chloroquine p. falciparum mefloquine p. vivax indicate
species-specific susceptibility profiles hdac inhibitors. hdac
inhibitors also found potent ex vivo p. vivax schizont
maturation, comparable p. falciparum, suggesting hdac inhibitors 
may promising candidates antimalarial therapy geographical locations
where species endemic. studies optimizing selectivity in
vivo efficacy hdac inhibitors plasmodium spp. defining drug interaction
with common antimalarial compounds warranted investigate role hdac 
inhibitors antimalarial therapy.

doi: 10.1128/aac.01220-10 
pmcid: pmc3067106
pmid: 21135175  [indexed medline]

